CN116196383A - 一种能舒畅肠道的槟榔用药食同源植物提取物及精制槟榔 - Google Patents
一种能舒畅肠道的槟榔用药食同源植物提取物及精制槟榔 Download PDFInfo
- Publication number
- CN116196383A CN116196383A CN202310006168.2A CN202310006168A CN116196383A CN 116196383 A CN116196383 A CN 116196383A CN 202310006168 A CN202310006168 A CN 202310006168A CN 116196383 A CN116196383 A CN 116196383A
- Authority
- CN
- China
- Prior art keywords
- medicinal
- plant extract
- betel nut
- refined
- edible plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000419 plant extract Substances 0.000 title claims abstract description 83
- 244000080767 Areca catechu Species 0.000 title claims abstract description 75
- 235000006226 Areca catechu Nutrition 0.000 title claims abstract description 74
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 21
- 235000018927 edible plant Nutrition 0.000 claims abstract description 78
- 241000700159 Rattus Species 0.000 claims abstract description 39
- 240000008154 Piper betle Species 0.000 claims abstract description 27
- 235000008180 Piper betle Nutrition 0.000 claims abstract description 27
- 230000000968 intestinal effect Effects 0.000 claims abstract description 26
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 19
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 19
- 230000004054 inflammatory process Effects 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 241000132012 Atractylodes Species 0.000 claims abstract description 17
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 210000001072 colon Anatomy 0.000 claims abstract description 16
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 16
- 235000008397 ginger Nutrition 0.000 claims abstract description 16
- 235000013976 turmeric Nutrition 0.000 claims abstract description 16
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 14
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 12
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 10
- 230000002550 fecal effect Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 238000004904 shortening Methods 0.000 claims abstract description 6
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 5
- 230000007246 mechanism Effects 0.000 claims abstract description 3
- 244000273928 Zingiber officinale Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000002791 soaking Methods 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 11
- 238000005187 foaming Methods 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 241001061264 Astragalus Species 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 210000004233 talus Anatomy 0.000 claims description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 235000019786 weight gain Nutrition 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 230000009266 disease activity Effects 0.000 claims description 5
- 230000004584 weight gain Effects 0.000 claims description 5
- 239000012676 herbal extract Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000004513 sizing Methods 0.000 claims description 4
- 241001127714 Amomum Species 0.000 claims description 3
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 3
- 229940107666 astragalus root Drugs 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 10
- 230000000770 proinflammatory effect Effects 0.000 abstract description 9
- 230000001055 chewing effect Effects 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 230000000050 nutritive effect Effects 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 2
- 230000000112 colonic effect Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 23
- 210000000952 spleen Anatomy 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 12
- 241000234314 Zingiber Species 0.000 description 12
- 101150096418 Mepe gene Proteins 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 238000005520 cutting process Methods 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000003825 pressing Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 238000004880 explosion Methods 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004026 adhesive bonding Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 210000000436 anus Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 5
- 229940041616 menthol Drugs 0.000 description 5
- 235000019477 peppermint oil Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 235000014375 Curcuma Nutrition 0.000 description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010024642 Listless Diseases 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017971 listlessness Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- -1 antiinflammatory Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010065611 Intestinal congestion Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种能舒畅肠道的槟榔用药食同源植物提取物,其所用原料黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄均归属2022年药食同源目录(国家卫键委公布),具有安全无毒、绿色健康的优点。该药食同源植物提取物可通过维持大鼠体重增长率,改善稀便、粪便隐血情况,降低DAI值;改善结肠缩短情况,保护结肠粘膜的完整性,减轻炎症对结肠的损伤;降低血清中促炎细胞因子TNF‑α和IL‑17水平,提高抗炎细胞因子TGF‑β水平等作用机制安全有效地预防和控制嚼食精制槟榔引起的便溏和肠道炎症。将该药食同源植物提取物应用于精制槟榔的降害生产,发挥药借食力,食助药威的优势,既赋予精制槟榔较高的营养价值,又可有效预防或控制嚼食精制槟榔引起的肠道炎症。
Description
技术领域
本发明涉及精制槟榔降害技术领域,特别涉及一种能舒畅肠道的槟榔用药食同源植物提取物以及具有该药食同源植物提取物的精制槟榔。
背景技术
槟榔(Areca catechu L.)为棕榈科槟榔属常绿乔木,富含生物碱、酚类、多糖、氨基酸等多种活性成分,具有促消化、降血糖、抗抑郁、抗氧化、抗炎、抗寄生虫和抑菌等作用。精制槟榔兴起于湖南湘潭,是以槟榔干果为原料,经清洗、杀菌、发籽、烤籽、切片、去核、点卤、晾片、包装等主要工序加工制作而成。
槟榔虽然具有很高的药用和经济价值,但近年来由于世卫组织将其列为一级致癌物,槟榔及其制品的安全性受到质疑,国家相关部门对精制槟榔的管控也越来越严厉。
流行病学调查结果表明,长期嚼食精制槟榔可致肠道功能紊乱,出现便溏、腹胀、嗳气、反酸等症状。现代毒理显示,小鼠灌胃精制槟榔提取液后中毒主要表现在肠道,可致出现腹泻便溏、肠壁水肿、肠道充血和出血症状,且剂量越大,症状越明显。先前的研究指出,人体70%的免疫力来自肠道,95%以上的感染性疾病与肠道相关。因此,针对精制槟榔肠道毒性开展降害技术研究显得尤为必要。然而,由于精制槟榔致肠道损伤的分子机制尚未明确,其相关降害技术研究至今仍处于空白状态。如何安全有效地预防或控制精制槟榔对肠道的损害,是当前及未来很长一段时间精制槟榔行业亟待解决的难点和重点问题。
发明内容
本发明所要解决的技术问题是针对现有技术空白,提供一种能舒畅肠道的槟榔用药食同源植物提取物以及具有该药食同源植物提取物的精制槟榔。
为解决上述技术问题,本发明提供以下技术方案:
一种能舒畅肠道的槟榔用药食同源植物提取物,其由下列重量份配比的药食同源植物原料制成:黄芪9–30、党参9–30、白术6–12、砂仁3–6、干姜3–10、甘草2–10、茯苓10–15、胎菊5–10和姜黄3–10。
原料最佳重量配比为:黄芪30、党参15、白术10、砂仁6、干姜6、甘草6、茯苓10、胎菊6和姜黄6。
制备方法主要包含以下步骤:
(1)将上述药食同源植物筛选后洗净,随即低温烘干后切碎,待用;
(2)将上述切碎的药食同源植物按重量配比混合,首次添加生药总重量8倍的蒸馏水浸泡30min;
(3)浸泡后大火煮沸,随后转小火煎煮1h,过滤300目滤布,得第一次水煎液;
(4)剩余滤渣中再次添加生药总重量4倍的蒸馏水继续煮沸熬煮1h后,过滤300目滤布,得第二次水煎液;
(5)合并两次水煎液,减压蒸馏至生药总重量的1.5–3倍,得浸膏;
(6)将浸膏冷冻干燥后,粉碎成粉状,即得该药食同源植物提取物。
动物实验结果显示,本发明的药食同源植物提取物可显著维持大鼠体重增长率,改善稀便、粪便隐血情况,降低疾病活动指数(Disease activity index,DAI)值;改善结肠缩短情况;降低血清中促炎细胞因子肿瘤坏死因子-α(Tumor necrosis factor alpha,TNF-α)和白细胞介素-17(Interleukin 17,IL-17)水平,提高抗炎细胞因子转化生长因子-β(Transforming growth factor-β,TGF-β)水平。
进一步地,所述药食同源植物提取物可以以粉状形态直接应用于精制槟榔生产的发制、焖香、上胶、点卤等工序中的其中一种或多种,或制成包含0.1–99%的该药食同源植物提取物,其余为载体或赋形剂的颗粒状、片状或胶囊状形态作为内含物点嵌于卤水中央应用。
本发明的有益效果在于:本发明提供了一种能舒畅肠道的槟榔用药食同源植物提取物,其所用原料黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄均归属2022年药食同源目录(国家卫键委公布),且每种原料的用量均在中国药典(2020年版)的用法用量限定范围,具有安全无毒、绿色健康的优点。该药食同源植物提取物具有健脾益气、清热燥湿、解毒敛创、凉血止血、柔肝止痛之功效,能够从根本上安全有效地预防或控制嚼食精制槟榔引起的肠道炎症。可通过维持大鼠体重增长率,改善稀便、粪便隐血情况,降低DAI值,改善结肠缩短情况,降低血清中促炎细胞因子TNF-α和IL-17水平,提高抗炎细胞因子TGF-β水平等作用机制安全有效地预防和控制嚼食精制槟榔引起的便溏和肠道炎症。将该药食同源植物提取物应用于精制槟榔的降害生产,发挥药借食力,食助药威的优势,既赋予精制槟榔较高的营养价值,又可有效预防和控制嚼食精制槟榔引起的肠道炎症。本发明不仅拓宽了药食同源食物深加工技术应用领域,还在增加精制槟榔产品附加值的同时提升了精制槟榔产业的经济效益和社会效益,促进了精制槟榔行业以健康为导向的可持续发展。
附图说明
图1是本发明实施例药食同源植物提取物改善了精制槟榔提取物引起的肠道炎症的示意图。灌胃期间大鼠体重(A)及体重增长率(B)变化。灌胃第30d大鼠粪便性状(C)。灌胃期间大鼠DAI值变化(D)。灌胃第30d大鼠回盲肠形态(E)及结肠长度(F)。
图2是精制槟榔提取物及本发明实施例药食同源植物提取物改变了大鼠血清细胞因子的表达的示意图。灌胃期间大鼠血清中IL-17(A)、TNF-α(B)和TGF-β(C)细胞因子水平。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
(一)一种药食同源植物提取物,所用原料主要包括:黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄。
实施例1:一种药食同源植物提取物中各原料的用量如下:黄芪30g、党参15g、白术10g、砂仁6g、干姜6g、甘草6g、茯苓10g、胎菊6g和姜黄6g。
实施例2:一种药食同源植物提取物中各原料的用量如下:黄芪30g、党参20g、白术8g、砂仁6g、干姜6g、甘草6g、茯苓8g、胎菊6g和姜黄6g。
实施例3:一种药食同源植物提取物中各原料的用量如下:黄芪30g、党参15g、白术10g、砂仁6g、干姜8g、甘草8g、茯苓15g、胎菊8g和姜黄8g。
实施例4:一种药食同源植物提取物中各原料的用量如下:黄芪30g、党参15g、白术10g、砂仁6g、干姜6g、甘草8g、茯苓15g、胎菊6g和姜黄8g。
实施例5:一种药食同源植物提取物中各原料的用量如下:黄芪30g、党参25g、白术12g、砂仁6g、干姜10g、甘草8g、茯苓15g、胎菊8g和姜黄6g。
(二)一种药食同源植物提取物的制备。
实施例6:一种药食同源植物提取物,由实施例1中的原料制成,制备方法包括以下步骤:
(1)将黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄筛选后洗净,随即低温烘干后切碎,待用;
(2)将黄芪30g、党参15g、白术10g、砂仁6g、干姜6g、甘草6g、茯苓10g、胎菊6g和姜黄6g混合,首次添加769g的蒸馏水浸泡30分钟;
(3)浸泡后大火煮沸,随后转小火煎煮1h,过滤300目滤布,得第一次水煎液;
(4)剩余滤渣中再次添加380g的蒸馏水继续煮沸熬煮1h后,过滤300目滤布,得第二次水煎液;
(5)合并两次水煎液,减压蒸馏至190g,得浸膏;
(6)将浸膏冷冻干燥后,粉碎成粉状,即得药食同源植物提取物。
(三)该药食同源植物提取物具有预防或控制由精制槟榔引起的便溏、肠道炎症的功效验证。
实施例7:为进一步验证本发明中药食同源植物提取物的舒畅肠道功效,采用实施例6所制备的药食同源植物提取物做生物活性实验,实验方法如下:
1材料与方法
1.1材料与试剂
动物:SPF级雄性Wister大鼠40只,8周龄,体质量200±20g,购自北京维通利华实验动物技术有限公司,动物许可证号SYXK(苏)。动物常规饲养于江南大学实验动物中心,相对湿度50–60%,室温22±2℃,昼夜交替照明,自由进食饮水,适应性饲养7d后开始实验。
材料:黄芪(批号:210901)、党参(批号210901)、白术(批号:210901)、砂仁(批号:210901)、干姜(批号:210901)、甘草(批号:210901)、茯苓(批号:210901)、胎菊(批号:210901)和姜黄(批号:210901),安国祁安药业有限公司,经鉴定符合《中华人民共和国药典》2020年版标准;槟榔片子(指以槟榔干果为原料,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核工艺制得的精制槟榔半成品)、卤料粉、薄荷脑和薄荷油,湖南伍子醉实业集团有限公司。
试剂:TNF-α、IL-17和TGF-β试剂盒,上海康朗生物科技有限公司;粪便隐血定性检测试剂盒(邻联甲苯胺法),北京雷根生物技术有限公司。
1.2仪器与设备
真空冷冻干燥机,美国LABCONCO公司;RE-52AA旋转蒸发器,上海亚荣生化仪器厂;ME103E电子天平,梅特勒-托利多上海有限公司;SpectraMax M2酶标仪,美国Molecular Devices公司。
1.3实验方法
1.3.1该药食同源植物提取物的制备
称取黄芪30g、党参15g、白术10g、砂仁6g、干姜6g、甘草6g、茯苓10g、胎菊6g和姜黄6g,用769g蒸馏水浸泡30min后,大火煮沸,随后转小火煎煮1h,过滤300目滤布,得第一次水煎液。剩余滤渣中再次添加380g的蒸馏水继续煮沸熬煮1h后,过滤300目滤布,得第二次水煎液。合并两次水煎液,减压蒸馏至190g,得浸膏。将浸膏冷冻干燥后,粉碎成粉状,即得该药食同源植物提取物(Rane)。
1.3.2精制槟榔提取物的制备
经前期产品调研和文献查阅分析得知,精制槟榔肠道毒性可能来源于槟榔干果中的一些化学成分(如生物碱)、卤水强碱性(pH=11.1±0.1,游离碱度82.95±5.41mg/g)及凉味剂(如薄荷脑和薄荷油)。预实验结果表明,以精制槟榔成品为原料提取得到的提取物呈酸性(pH=6.65±0.3),且卤水中添加的薄荷脑和薄荷油在提取过程中易挥发。因此,为尽可能模拟研究精制槟榔原料化学成分、卤料及凉味剂对肠道的影响,本实验以槟榔片子为原料,采用与药食同源植物提取物相同的制备方法,提取得到槟榔片子提取物(总生物碱含量为17.92mg/g,总生物碱含量以槟榔碱、槟榔次碱、去甲槟榔碱和去甲槟榔次碱含量之和计算),再额外添加一定配比的卤料粉、薄荷脑和薄荷油的方式制备得到精制槟榔提取物(Mepe)。
1.3.3动物实验与分组
32只Wister大鼠适应性喂养一周后,随机分为4组(NC、Mepe、Rane-L、Rane-H),每组8只,每只动物按1mL/100g的剂量每日灌胃一次,连续灌胃30d。正常组(NC)每日给予蒸馏水;精制槟榔组(Mepe)以70kg成人每日摄入100g精制槟榔(剂量相当于摄入总生物碱245.44mg,卤水粉12.77g,薄荷脑0.36g,薄荷油1.43g)的剂量,参照徐叔云教授主编的《药理实验方法学》,按人与大鼠体表面积折算的等效计量系数(0.018)换算成大鼠剂量,每日给予精制槟榔提取物;Rane-L和Rane-H组每日给予精制槟榔提取物的同时给予该药食同源植物提取物。各组具体给药情况见表1-1。
表1-1实验动物分组及灌胃情况
注:*,剂量相当于70kg成人推荐剂量的6.3倍;#,剂量相当于70kg成人推荐剂量的12.6倍。
1.3.4疾病活动指数评分
整个实验期间,每3d观察并记录大鼠的一般情况,包括精神状态、活动、大鼠的粪便性状及便血情况,按表1-2标准,计算DAI值。
DAI=(体质量下降分值+粪便性状分值+便血情况分值)/3
表1-2DAI评分标准
注:*,粪便性状分值的评分依据为黏着于肛门的水样便为稀便,不黏着于肛门的糊状水样便为半稀便,成型大便为正常便。
1.3.5标本采集
最后一次灌胃结束后,各组动物禁食不禁水12h,采用异氟烷麻醉大鼠,心脏采血,3000rmp室温离心10min分离上层血清,备用。随后以安尔碘腹部消毒后,用消毒后的器械分离肛门至回盲肠管,测量肛门至回盲部肠管长度。
1.3.6大鼠血清炎症因子水平的测定
取分离的血清,按ELISA试剂盒说明书检测血清中TNF-α、IL-17和TGF-β水平。
1.3.7数据统计与分析
采用Origin 2017软件进行数据处理和作图,采用SPSS 20.0软件进行单因素方差分析(ANOVA),若存在统计学差异,进一步应用LSD法进行两两比较。
2结果与分析
2.1精制槟榔提取物及该药食同源植物提取物对大鼠体重变化率、疾病活动指数及结肠长度的影响
灌胃期间,大鼠体重持续增加,由灌胃第0d的259.83±2.05g增长至灌胃第30d的401.67±22.22g(图1A)。CN组大鼠在灌胃结束时体重增加了64.32%,精制槟榔提取物可显著降低大鼠体重增长率(P<0.05),直至灌胃第30d,大鼠体重仅增加45.68%(图1B)。采用该药食同源植物提取物干预后,大鼠体重增长率明显回升,尤其是Rane-H组,灌胃结束时大鼠体重增长了58.53%(图1B)。
DAI值是评估大鼠肠道炎症的重要指标,如图1D所示,NC组大鼠在灌胃期间精神活跃、毛色光泽发亮,且体重稳定上升、大便成形、无便血情况,而Mepe组大鼠第3d开始DAI值上升,出现精神萎靡、大便带粘液等症状,第9d出现粪便隐血情况,并伴随水状粪便、肛门肿胀等现象,第30d时DAI升高至2.67。相较而言,Rane组情况有所改善,灌胃结束时Rane-L和Rane-H两组的DAI值分别仅为1.67和1(图1D),结果表明药食同源植物提取物能显著改善精制槟榔提取物引起的肠道炎症病状(P<0.05)。从灌胃第30d各组大鼠的粪便性状上(图1C),也可得出上述结论。
结肠萎缩是炎症性肠病的主要症状之一,如图1E-F所示,CN组大鼠结肠长度为17.84±1.69cm,Mepe组为12.17±1.43cm,明显缩短(P<0.001),Rane-L和Rane-H组结肠长度分别为15.78±1.89cm和17.73±1.58cm,结果表明该药食同源植物提取物能显著控制精制槟榔提取物引起的结肠长度缩短(P<0.001)。
2.2精制槟榔提取物及该药食同源植物提取物对大鼠血清炎症因子水平的影响
炎症因子是一类主要由免疫系统细胞分泌的具有多种生物学效应的内源性多肽,可介导单核细胞等炎症细胞浸润肠组织引起肠组织损伤,直观反映肠道的炎症程度。IL-17和TNF-α等促炎症因子分泌水平异常升高或TGF-β等抗炎症因子分析水平异常降低均会促使大鼠肠道炎性损伤加剧。TNF-α是炎症反应中出现最早、最重要的炎性介质,能够协同干扰素γ改变肠上皮细胞的屏障功能和形态结构,增加肠黏膜和血管壁的通透性,引起肠壁出现溃疡和水肿;IL-17是T细胞诱导炎症反应的早期启动因子,可以通过促进释放前炎性细胞因子来放大炎症反应;TGF-β是一种多功能细胞因子,表现在创伤修复、免疫调节、细胞凋亡等多个方面。
如图2所示,与CN组相比,Mepe组大鼠血清中促炎症因子水平显著提高(P<0.001),抗炎症因子水平显著降低(P<0.001);与Mepe组相比,药食同源植物提取物干预组促炎因子水平显著降低(P<0.001),其中Rane-L和Rane-H组能使IL-17水平相较于Mepe组分别降低9.27%和15.47%,使TNF-α水平分别降低0.89%和1.46%。此外Rane-L和Rane-H组TGF-β水平相较于Mepe组分别升高12.55%和15.88%。本研究发现该药食同源植物提取物能通过抑制促炎症因子水平升高和促进抗炎症因子分泌,缓解精制槟榔提取物引起的肠道炎症病理过程中的炎症反应。
3结论
综上所述,精制槟榔提取物可引起肠道炎症,使大鼠体重增长率显著降低(P<0.05),导致DAI值升高和结肠萎缩,同时促进血清IL-17和TNF-α水平升高,抑制TGF-β分泌。在该药食同源植物提取物的干预下,精制槟榔提取物引起的肠道炎症得到明显改善,具体表现在大鼠体重增长率显著回升(P<0.05),DAI值显著降低(P<0.05),大鼠结肠缩短现象得到缓解,此外该药食同源植物提取物显著抑制了大鼠血清中促炎症因子的升高(P<0.001),促进了抗炎症因子的分泌(P<0.001)。该药食同源植物提取物的作用效果呈现明显的剂量依赖性。
(四)该药食同源植物提取物的理论依据
便溏、腹胀、嗳气、反酸是肠道炎症的典型症状,中医学认为情志不调、肝气横逆犯脾、脾病湿盛、或禀赋不足、脾失温煦、积谷为滞、或气治血阻、肠道不利、血迫大肠、或后天饮食不节(洁)是其主要病机。药食同源植物因其安全性高,且兼具食物丰富的营养价值和中药的药用价值,在食源性肠道炎症的预防和控制领域表现出了极高的开发和利用价值。
本实施例中的药食同源植物提取物所用原料黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄均归属2022年药食同源目录(国家卫键委公布),其中黄芪味甘,性微温,归肺、脾经,有补气升阳、固表止汗、利水消肿、生津养血、行滞通痹、托毒排脓、敛疮生肌的功效,主治气虚乏力、食少便溏、中气下陷、久泻脱肛、便血崩漏、表虚自汗、气虚水肿、内热消渴、血虚萎黄、半身不遂、痹痛麻木、痈疽难溃、久溃不敛;党参味甘,性平,归脾、肺经,有健脾益肺、养血生津的功效,主治脾肺气虚、食少倦怠、咳嗽虚喘、气血不足、面色萎黄、心悸气短、津伤口渴、内热消渴;白术味苦、甘,性温,归脾、胃经,有健脾益气、燥湿利水、止汗、安胎的功效,主治脾虚食少、腹胀泄泻、痰饮眩悸、水肿、自汗、胎动不安;砂仁味辛,性温,归脾、胃、肾经,有化湿开胃、温脾止泻、理气安胎的功效,主治湿浊中阻、脘痞不饥、脾胃虚寒、呕吐泄泻、妊娠恶阻、胎动不安;干姜味辛,性热,归脾、胃、肾、心、肺经,有温中散寒、回阳通脉、温肺化饮的功效,主治脘腹冷痛、呕吐泄泻、肢冷脉微、寒饮喘咳;甘草味甘,性平,归心、肺、脾、胃经,有补脾益气、清热解毒、祛痰止咳、缓急止痛、调和诸药的功效,主治脾胃虚弱、倦怠乏力、心悸气短、咳嗽痰多、脘腹、四肢挛急疼痛、痈肿疮毒、缓解药物毒性、烈性;茯苓味甘、淡,性平,归心、肺、脾、肾经,有利水渗湿、健脾、宁心的功效,主治水肿尿少、痰饮眩悸、脾虚食少、便溏泄泻、心神不安、惊悸失眠;胎菊味甘、苦,性微寒,归肺、肝经,有散风清热、平肝明目、清热解毒的功效,主治风热感冒、头痛眩晕、目赤肿痛、眼目昏花、疮痈肿毒;姜黄味辛、苦,性温,归脾、肝经,有破血行气、通经止痛的功效,主治胸胁刺痛、胸痹心痛、痛经经闭、癥瘕、风湿肩臂疼痛、跌扑肿痛。本实施例中的药食同源植物提取物具有健脾清热、利湿止痛的功效,将其应用于精制槟榔的降害生产,发挥药借食力,食助药威的优势,既赋予精制槟榔较高的营养价值,又可有效预防和控制嚼食精制槟榔引起的肠道炎症。本实施例不仅拓宽了药食同源食物深加工技术应用领域,还在增加精制槟榔产品附加值的同时提升了精制槟榔产业的经济效益和社会效益。
(五)该药食同源植物提取物在精制槟榔降害产品中的应用
实施例8:采用实施例6所制备的药食同源植物提取物粉末应用于发制工序制备降害精制槟榔产品,具体实施是以发制液与该药食同源植物提取物质量比为1:2的比例于发制液中添加该药食同源植物提取物粉末,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
实施例9:采用实施例6所制备的药食同源植物提取物粉末应用于焖香工序制备降害精制槟榔产品,具体实施是以焖香液与该药食同源植物提取物质量比为1:1.5的比例于焖香液中添加该药食同源植物提取物粉末,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
实施例10:采用实施例6所制备的药食同源植物提取物粉末应用于上胶工序制备降害精制槟榔产品。具体实施是以胶液与该药食同源植物提取物质量比为1:1的比例于上胶液中添加该药食同源植物提取物粉末,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
实施例11:采用实施例6所制备的药食同源植物提取物粉末与蔗糖、玉米淀粉、糊精等辅料制成颗粒应用于点卤工序制备降害精制槟榔产品。该药食同源植物提取物颗粒的具体制备步骤为:将糊精以料液比为1:3的比例与80℃的蒸馏水混合,保持在80℃条件下进行溶解,待糊精与水分散均匀形成糊状的糊精水溶液后,以料液比为1.5:1的比例添加该药食同源植物提取物粉末,保持在60℃条件下进行混合,搅拌均匀,随后再与适量预混辅料蔗糖-玉米淀粉混合,干法制粒,即得。将上述制备好的药食同源植物提取物颗粒以0.5g/5g槟榔的量点嵌于卤料中央,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
实施例12:采用实施例6所制备的药食同源植物提取物粉末与麦芽糊精、麦芽糖醇等辅料制成咀嚼片后应用于点卤工序制备降害精制槟榔产品。该药食同源植物提取物咀嚼片的具体制备步骤为:将该药食同源植物提取物与微晶纤维、麦芽糖醇、麦芽糊精以10:2:2:10的比例混合均匀后,再添加适量硬脂酸镁,进一步混合均匀后压片,即得。将上述制备好的药食同源植物提取物咀嚼片以0.5g/5g槟榔的量点嵌于卤料中央,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
实施例13:采用实施例6所制备的药食同源植物提取物粉末与明胶、甘油等辅料制成软胶囊后应用于点卤工序制备降害精制槟榔产品。该药食同源植物提取物软胶囊的具体制备步骤为:将明胶倒入蒸馏水中进行加热浸泡后融化,随后再加入甘油进行搅拌,再经静止脱泡、过滤,得胶液;以料液比2:1的比例将该药食同源植物提取物与水混合均匀,得心液;将制备好的心液和胶液放置于胶囊压丸机中,压制成胶囊,并用冷风进行固化成型,再用热风进行干燥。将上述制备好的药食同源植物提取物软胶囊以0.5g/5g槟榔的量点嵌于卤料中央,经泡籽—汽爆—发制—烤籽—焖香—压籽—上胶—晾籽—切籽—去核—点卤—晾片—包装工艺制得精制槟榔降害产品。
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管通过参照本发明的优选实施例已经对本发明进行了描述,但本领域的普通技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离所附权利要求所限定的本发明的精神和范围。
Claims (8)
1.一种能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,所述药食同源植物提取物的原料主要包括:黄芪、党参、白术、砂仁、干姜、甘草、茯苓、胎菊和姜黄。
2.如权利要求1所述的能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,它是由下列重量份配比的药食同源植物原料制成:黄芪9–30、党参9–30、白术6–12、砂仁3–6、干姜3–10、甘草2–10、茯苓10–15、胎菊5–10和姜黄3–10。
3.如权利要求1所述的能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,它是通过以下步骤制备:取黄芪9–30g、党参9–30g、白术6–12g、砂仁3–6g、干姜3–10g、甘草2–10g、茯苓10–15g、胎菊5–10g和姜黄3–10g,添加生药总重量8倍的蒸馏水浸泡30min后,于煮沸条件下熬煮1h,随后以300目滤布过滤,收集滤液;剩余滤渣添加生药总重量4倍的蒸馏水继续煮沸熬煮1h后,过滤300目滤布,合并滤液;滤液经减压蒸馏至膏体,随后冷冻干燥,粉碎即得药食同源植物提取物。
4.如权利要求1–3任意一项所述的能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,所述药食同源植物提取物具有预防或控制由精制槟榔引起的便溏、肠道炎症的作用。
5.如权利要求4所述的能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,所述药食同源植物提取物发挥舒畅肠道功效的机制包括:维持大鼠体重增长率,改善稀便、粪便隐血情况,降低疾病活动指数;改善结肠缩短情况,保护结肠组织结构完整性;降低促炎细胞因子肿瘤坏死因子-α和白细胞介素-17水平,提高抗炎细胞因子转化生长因子-β水平。
6.如权利要求1–3任意一项所述的能舒畅肠道的槟榔用药食同源植物提取物,其特征在于,所述药食同源植物提取物在应用时,直接使用或者以组合物的形式使用,所述组合物包括0.1–99%的药食同源植物提取物,其余为载体或赋形剂,所述药食同源植物提取物的应用形态为粉状、颗粒状、片状或胶囊状。
7.一种精制槟榔,其特征在于,包括槟榔片子、卤料与药食同源植物提取物,所述槟榔片子是以槟榔干果为主要原料加工制作而成的产品;所述卤料是以食糖、淀粉糖为主要原料,辅以其它配料,经熬制而成的糊状物;所述药食同源植物提取物为如权利要求1-6任意一项所述的能舒畅肠道的槟榔用药食同源植物提取物;所述药食同源植物提取物结合于槟榔片子上或点嵌于卤料上。
8.如权利要求7所述的精制槟榔,其特征在于,所述药食同源植物提取物在应用时,以粉状形态应用于精制槟榔生产的发制、焖香、上胶、点卤工序中的其中一种或多种,或以颗粒状、片状或胶囊状形态点嵌于卤料中央。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310006168.2A CN116196383B (zh) | 2023-01-04 | 2023-01-04 | 一种用于预防和控制嚼食精制槟榔引起的便溏和肠道炎症的药食同源植物提取物及精制槟榔 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310006168.2A CN116196383B (zh) | 2023-01-04 | 2023-01-04 | 一种用于预防和控制嚼食精制槟榔引起的便溏和肠道炎症的药食同源植物提取物及精制槟榔 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116196383A true CN116196383A (zh) | 2023-06-02 |
CN116196383B CN116196383B (zh) | 2024-02-13 |
Family
ID=86510548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310006168.2A Active CN116196383B (zh) | 2023-01-04 | 2023-01-04 | 一种用于预防和控制嚼食精制槟榔引起的便溏和肠道炎症的药食同源植物提取物及精制槟榔 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116196383B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101108244A (zh) * | 2007-06-14 | 2008-01-23 | 王俊荣 | 益气健脾的中药方剂 |
CN101130023A (zh) * | 2007-08-21 | 2008-02-27 | 王军 | 党参温胃散 |
CN106729570A (zh) * | 2017-01-22 | 2017-05-31 | 吴冬梅 | 祛湿除热消炎汤 |
CN109303895A (zh) * | 2017-07-27 | 2019-02-05 | 李祝春 | 一种治疗慢性肠炎的中药组合物 |
CN114712478A (zh) * | 2021-01-05 | 2022-07-08 | 金陵药业股份有限公司 | 一种治疗肠道疾病的中药组合物、制剂及其制备方法 |
CN115154563A (zh) * | 2022-07-05 | 2022-10-11 | 威海市中医院(山东中医药大学附属威海市中医院) | 预防溃疡性结肠炎复发的药物组合物 |
-
2023
- 2023-01-04 CN CN202310006168.2A patent/CN116196383B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101108244A (zh) * | 2007-06-14 | 2008-01-23 | 王俊荣 | 益气健脾的中药方剂 |
CN101130023A (zh) * | 2007-08-21 | 2008-02-27 | 王军 | 党参温胃散 |
CN106729570A (zh) * | 2017-01-22 | 2017-05-31 | 吴冬梅 | 祛湿除热消炎汤 |
CN109303895A (zh) * | 2017-07-27 | 2019-02-05 | 李祝春 | 一种治疗慢性肠炎的中药组合物 |
CN114712478A (zh) * | 2021-01-05 | 2022-07-08 | 金陵药业股份有限公司 | 一种治疗肠道疾病的中药组合物、制剂及其制备方法 |
CN115154563A (zh) * | 2022-07-05 | 2022-10-11 | 威海市中医院(山东中医药大学附属威海市中医院) | 预防溃疡性结肠炎复发的药物组合物 |
Non-Patent Citations (9)
Title |
---|
侯杰;: "中西医结合治疗56例溃疡性结肠炎的临床疗效观察", 现代诊断与治疗, vol. 25, no. 17, pages 3915 - 3916 * |
刘再平: "内服中药合外敷神厥穴治疗慢性非特异性溃疡性结肠炎47例", 广西中医药, vol. 27, no. 04, pages 34 - 35 * |
刘尔卓等: "基于高通量测序分析鲜槟榔水提液对于小鼠肠道菌群及免疫指标的影响", 食品研究与开发, vol. 41, no. 10, pages 28 - 33 * |
宇傲霜, 王红梅, 任文海: "中西医结合治疗溃疡性结肠炎的疗效观察", 现代中西医结合杂志, vol. 9, no. 21, pages 2095 - 2096 * |
景慧 , 刘建邦: "四君子汤加味治疗慢性结肠炎46例体会", 新疆中医药, vol. 20, no. 03, pages 21 - 22 * |
林汉杰;张金卫;卢月;危建安;孙静;黎莉;韩凌;: "四君子汤对UC模型大鼠的治疗作用及其对紧密连接蛋白Occludin表达的影响", 中国实验方剂学杂志, vol. 22, no. 13, pages 112 - 117 * |
熊鹰, 陈如山, 王建平, 张永锋, 关宏: "结肠康泰对大鼠结肠炎肠组织内TNF-α、IL-1β、IL-6水平的影响", 中国病理生理杂志, vol. 18, no. 09, pages 1137 - 1138 * |
王文友, 魏文斌: "辨证治疗慢性结肠炎48例", 北京中医, no. 02, pages 30 - 31 * |
高福东;赵东;薛玲;张惠云;: "结肠清颗粒对结肠炎模型大鼠一氧化氮和髓过氧化物酶的影响", 山东中医杂志, vol. 28, no. 08, pages 574 - 576 * |
Also Published As
Publication number | Publication date |
---|---|
CN116196383B (zh) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101181495B (zh) | 一种具有响声作用的配方及其应用 | |
CN104001045A (zh) | 一种用于治疗犬肺炎的药物及其制备方法 | |
CN103417911B (zh) | 化疗辅助用中药组合物 | |
CN116196383B (zh) | 一种用于预防和控制嚼食精制槟榔引起的便溏和肠道炎症的药食同源植物提取物及精制槟榔 | |
CN102552796B (zh) | 一种治疗慢性胃溃疡的中药组合物 | |
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN108125237B (zh) | 一种镇咳祛痰抗炎的保健品及其制备工艺 | |
CN103041079B (zh) | 无糖型麻苏止咳复方制剂的制备方法 | |
WO2015149391A1 (zh) | 一种治疗慢性肠炎的中药制剂及其制备方法 | |
CN104173812A (zh) | 用于治疗血热妄行型急性特发性血小板减少性紫癜的药物组合物及其制备方法 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN116712523B (zh) | 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 | |
CN103705692B (zh) | 一种治疗急性胃肠炎的中药制剂 | |
CN107801824B (zh) | 一种通便保健代用茶的制备方法 | |
CN104825977A (zh) | 一种治疗脾虚伤食型产后伤食的中药组合物及制备方法 | |
CN108066437B (zh) | 一种中药组合物及其制备方法 | |
CN108404068B (zh) | 一种治疗和/或预防腹泻的药物组合物及其制备方法 | |
CN105055806A (zh) | 一种用于治疗腹泻的药物制剂 | |
CN105434670A (zh) | 一种治疗肋软骨炎的中药制剂及其制备方法 | |
CN104706866A (zh) | 一种治疗肠炎的中药制剂及制备方法 | |
CN104398902A (zh) | 虚寒型慢性支气管炎清热宣肺制剂及制法 | |
WO2015149392A1 (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 | |
CN103933427A (zh) | 用于治疗结节性霉素疹的药物组合物及其制备方法 | |
CN113546108A (zh) | 一种治疗功能性消化不良的药物组合物及其制备方法 | |
CN113398215A (zh) | 治疗肺及结肠肿瘤癌前病变的中药组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |